Dong Yubing, Wang Guohao, Ujihara Yoshihiro, Chen Yanzhu, Yoshida Masashi, Nakamura Kazufumi, Katanosaka Kimiaki, Naruse Keiji, Katanosaka Yuki
Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Department of Pharmacy, College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi, Japan.
Commun Biol. 2025 May 8;8(1):715. doi: 10.1038/s42003-025-08167-9.
The heart dynamically compensates for haemodynamic stress, but how this resilience forms during cardiac growth is not clear. Using a temporally inducible, cardiac-specific knockout in mice we show that the Transient receptor potential vanilloid family 2 (TRPV2) channel is crucial for the maturation of cardiomyocyte stress resilience. TRPV2 defects in growing hearts lead to small morphology, abnormal intercalated discs, weak contractility, and low expression of serum response factor and Insulin-like growth factor-1 (IGF-1) signalling. Individual cardiomyocytes of TRPV2-deficient hearts show reduced contractility with abnormal Ca handling. In cultured neonatal cardiomyocytes, mechanical Ca response, excitation-contraction coupling, sarcoplasmic reticulum Ca content, actin formation, nuclear localisation of Myocyte enhancer factor 2c, and IGF-1 expression require TRPV2. TRPV2-deficient hearts show a defective response to dobutamine stress and no compensatory hypertrophic response to phenylephrine administration, but no stress response to pressure overload. These data suggest TRPV2 mediates the maturation of cardiomyocyte stress resilience, and will advance therapeutic interventions and drug discovery for heart disease.
心脏会动态地代偿血流动力学应激,但这种适应性在心脏生长过程中是如何形成的尚不清楚。我们利用一种可在特定时间诱导的小鼠心脏特异性基因敲除模型,证明瞬时受体电位香草酸亚型2(TRPV2)通道对心肌细胞应激适应性的成熟至关重要。生长中的心脏中TRPV2缺陷会导致心脏形态变小、闰盘异常、收缩力减弱以及血清反应因子和胰岛素样生长因子-1(IGF-1)信号表达降低。TRPV2缺陷心脏的单个心肌细胞收缩力降低,钙处理异常。在培养的新生心肌细胞中,机械性钙反应、兴奋-收缩偶联、肌浆网钙含量、肌动蛋白形成、心肌增强因子2c的核定位以及IGF-1表达均需要TRPV2。TRPV2缺陷心脏对多巴酚丁胺应激反应存在缺陷,对去氧肾上腺素给药无代偿性肥厚反应,但对压力超负荷无应激反应。这些数据表明TRPV2介导心肌细胞应激适应性的成熟,将推动心脏病治疗干预措施和药物研发。